
Sarah Gregory

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2329638/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	6.1	122
2	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	10.2	122
3	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. Brain, 2015, 138, 3327-3344.	7.6	96
4	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.1	65
5	Operationalizing compensation over time in neurodegenerative disease. Brain, 2017, 140, 1158-1165.	7.6	62
6	In vivo characterization of white matter pathology in premanifest huntington's disease. Annals of Neurology, 2018, 84, 497-504.	5.3	53
7	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	9.0	44
8	Measuring compensation in neurodegeneration using MRI. Current Opinion in Neurology, 2017, 30, 380-387.	3.6	37
9	Testing a longitudinal compensation model in premanifest Huntington's disease. Brain, 2018, 141, 2156-2166.	7.6	33
10	Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease. Biological Psychiatry, 2021, 89, 807-816.	1.3	32
11	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. Frontiers in Neurology, 2017, 8, 519.	2.4	31
12	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. Human Brain Mapping, 2017, 38, 2819-2829.	3.6	28
13	11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis. Metabolism: Clinical and Experimental, 2020, 108, 154246.	3.4	26
14	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 143-149.	1.9	26
15	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. NeuroImage: Clinical, 2018, 17, 312-324.	2.7	23
16	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. Annals of Neurology, 2020, 87, 751-762.	5.3	22
17	Diffusion imaging in Huntington's disease: comprehensive review. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 62-69.	1.9	22
18	Huntington's disease: Brain imaging in Huntington's disease. Progress in Molecular Biology and Translational Science, 2019, 165, 321-369.	1.7	20

SARAH GREGORY

#	Article	IF	CITATIONS
19	Characterizing White Matter in Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 52-60.	1.5	20
20	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. EBioMedicine, 2021, 65, 103266.	6.1	20
21	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. Neurology: Genetics, 2021, 7, e617.	1.9	20
22	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. Human Brain Mapping, 2018, 39, 3516-3527.	3.6	19
23	Experiences of hearing aid use among patients with mild cognitive impairment and Alzheimer's disease dementia: A qualitative study. SAGE Open Medicine, 2020, 8, 205031212090457.	1.8	15
24	Establishing the motivations of patients with dementia and cognitive impairment and their carers in joining a dementia research register (DemReg). International Psychogeriatrics, 2013, 25, 963-971.	1.0	14
25	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	9.0	12
26	Composite <scp>UHDRS</scp> Correlates With Progression of Imaging Biomarkers in Huntington's Disease. Movement Disorders, 2021, 36, 1259-1264.	3.9	12
27	Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington's disease. Brain, 2022, 145, 991-1000.	7.6	11
28	Timing of selective basal ganglia white matter loss in premanifest Huntington's disease. NeuroImage: Clinical, 2022, 33, 102927.	2.7	10
29	Effectiveness of eccentric-biased exercise interventions in reducing the incidence of falls and improving functional performance in older adults: a systematic review. European Geriatric Medicine, 2022, 13, 367-380.	2.8	9
30	Therapeutic implications of hypothalamic-pituitaryadrenal-axis modulation in Alzheimer's disease: A narrative review of pharmacological and lifestyle interventions. Frontiers in Neuroendocrinology, 2021, 60, 100877.	5.2	8
31	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. BMJ Open, 2022, 12, e052250.	1.9	7
32	Functional Magnetic Resonance Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 381-408.	2.0	6
33	Involving research participants in a pan-European research initiative: the EPAD participant panel experience. Research Involvement and Engagement, 2020, 6, 62.	2.9	6
34	Longitudinal Structural <scp>MRI</scp> in Neurologically Healthy Adults. Journal of Magnetic Resonance Imaging, 2020, 52, 1385-1399.	3.4	5
35	Development of a core competency framework for clinical research staff. Journal of Interprofessional Education and Practice, 2020, 18, 100301.	0.4	4
36	Neurofilament light-associated connectivity in young-adult Huntington's disease is related to neuronal genes. Brain, 2022, 145, 3953-3967.	7.6	3

SARAH GREGORY

#	Article	IF	CITATIONS
37	Magnetic Resonance Imaging in Huntington's Disease. Methods in Molecular Biology, 2018, 1780, 303-328.	0.9	2
38	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease. Frontiers in Big Data, 2021, 4, 662200.	2.9	2
39	Building a Systematic Online Living Evidence Summary of COVID-19 Research. Journal of the European Association for Health Information and Libraries, 2021, 17, 21-26.	0.2	1
40	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 910-918.	1.5	1
41	D18â€Brain network breakdown and pathophysiological correlates in huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A40.2-A40.	1.9	0
42	D21â€Longitudinal compensation in the cognitive network in huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.1-A42.	1.9	0
43	D20â€Operationalising compensation over time in neurodegenerative disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A41.2-A41.	1.9	0
44	D22â€Compensation in preclinical huntington's disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	1.9	0
45	1609â€Length of white matter connexions determine their rate of atrophy in premanifest huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A9.2-A9.	1.9	0
46	D10â€Neurofilament light protein in blood predicts regional atrophy in huntington's disease. , 2018, , .		0
47	E11â€Compensation in huntington's disease. , 2018, , .		0
48	Multimodal characterization of the visual network in Huntington's disease gene carriers. Clinical Neurophysiology, 2019, 130, 2053-2059.	1.5	0
49	9â€Aberrant striatal value representation in Huntington's disease gene carriers 25 years before onset. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, e4.1-e4.	1.9	0
50	F05â€Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
51	E01 $\hat{a}\in$ Modelling the trajectory of cortical atrophy in huntington $\hat{a}\in$ ^M s disease. , 2018, , .		0
52	F59â€Huntington's disease young adult study (HD-YAS). , 2018, , .		0
53	Diseases with abnormal HPA function predict CSF pTau but not CSF Abeta 1â€42 in the EPAD longitudinal cohort study. Alzheimer's and Dementia, 2021, 17, .	0.8	0